AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12131112 — intervention group
Group type: EXPERIMENTAL
Intervention: ReAMR group (5 microg x kg(‐1) x min(‐1) amrinone with 1.0‐mg/kg loading and reloading doses)
Number of subjects: 30
Study 12131112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amrinone)
Number of subjects: 30
Study 10343521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ) 2-3 g/day
Number of subjects: 105
Study 10343521 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5-15 mg/week
Number of subjects: 105
Study 10343521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sulphasalazine and Methotrexate (COMBI) same dose range as above
Number of subjects: 105
Study 10343521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients homozygous for the C677T mutation in MTHFR gene
Number of subjects: 105
Study 10343521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients heterozygous for the C677T mutation in MTHFR gene
Number of subjects: 105
Study 10343521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gastrointestinal toxicity
Number of subjects: 105
Study 10343521 — intervention group
Group type: COMPARATOR
Intervention: Clinical efficacy variables
Number of subjects: 105
Study 7856896 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (50-100 micrograms)
Number of subjects: 20
Study 7856896 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (50-100 micrograms)
Number of subjects: 20
Study 1974395 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with vecuronium (0.01 mg/kg priming dose, 4‐min priming interval, 0.14‐mg/kg intubating dose along with thiopental 4‐6 mg iv)
Number of subjects: 60
Study 1974395 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing with vecuronium (0.15‐mg/kg intubating dose given before thiopental and timed to weakness of hand grip)
Number of subjects: 60
Study 1974395 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 60
Study 7400477 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide, 50 micrograms four times per day
Number of subjects: 0
Study 7400477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31929136 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing and segmental stabilization exercises (RE+LSSE)
Number of subjects: 59
Study 31929136 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental stabilization exercises (LSSE)
Number of subjects: 59
Study 31929136 — intervention group
Group type: COMPARATOR
Intervention: Modality treatment (Control)
Number of subjects: 59
Study 29576128 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing without leak (SB)
Number of subjects: 20
Study 29576128 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing with calibrated air leak (SB-leak)
Number of subjects: 20
Study 29576128 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation with calibrated leak (PPV-leak)
Number of subjects: 20
Study 28556586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 417
Study 28556586 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 417
Study 26142575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual intercourse 3-4 times a week
Number of subjects: 75
Study 26142575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/d
Number of subjects: 75
Study 26142575 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (Control)
Number of subjects: 75
Study 24104790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10 mg tablet orally up to five doses)
Number of subjects: 60
Study 24104790 — intervention group
Group type: COMPARATOR
Intervention: Intravenous labetalol (escalating doses of 20, 40, 80, 80, and 80 mg)
Number of subjects: 60
Study 24104790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 60
Study 24104790 — intervention group
Group type: COMPARATOR
Intervention: Intravenous labetalol
Number of subjects: 60
Study 21221853 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-based therapy (PBT)
Number of subjects: 2115
Study 18413818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin exposure with ODC 316AA genotype
Number of subjects: 2207
Study 18413818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin exposure with homozygous ODC 316AA genotype
Number of subjects: 2207
Study 18413818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin exposure with wild-type or heterozygous genotypes
Number of subjects: 2207
Study 18413818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin exposure with both ODC 316AA genotype
Number of subjects: 2207
Study 16580520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1058
Study 16580520 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1058
Study 12213665 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopanoic acid (IOP) for 7 days
Number of subjects: 14
Study 12213665 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated solution of potassium iodide (SSKI) for 10-15 days
Number of subjects: 14
Study 12213665 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IOP and SSKI
Number of subjects: 14
Study 9828818 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry using HMB‐45 antibody
Number of subjects: 32
Study 9828818 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR for tyrosinase
Number of subjects: 32
Study 9828818 — intervention group
Group type: COMPARATOR
Intervention: Routine histology
Number of subjects: 32
Study 8133366 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction with a median of 4 weeks of maxillomandibular fixation
Number of subjects: 101
Study 8133366 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repositioning and transosseous wiring of the dislocated condylar fragment with a median of 6 weeks of maxillomandibular fixation
Number of subjects: 101
Study 2696850 — intervention group
Group type: EXPERIMENTAL
Intervention: R 76713 (5 mg)
Number of subjects: 15
Study 2696850 — intervention group
Group type: EXPERIMENTAL
Intervention: R 76713 (10 mg)
Number of subjects: 15
Study 2696850 — intervention group
Group type: EXPERIMENTAL
Intervention: R 76713 (20 mg)
Number of subjects: 15
Study 2696850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4887385 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin (up to 300 mg daily)
Number of subjects: 90
Study 4887385 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 3 g daily)
Number of subjects: 90
Study 4887385 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 4887385 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin and Metformin (combined)
Number of subjects: 90
Study 7189149 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning types (M)
Number of subjects: 0
Study 7189149 — intervention group
Group type: COMPARATOR
Intervention: Evening types (E)
Number of subjects: 0
Study 7189149 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian trends in correct rejection levels and body temperature for E types
Number of subjects: 0
Study 7189149 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian trends in correct rejection levels and body temperature for M types
Number of subjects: 0
Study 30874252 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration technique (Icon)
Number of subjects: 21
Study 30874252 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐assembling peptide (Curodont Repair)
Number of subjects: 21
Study 30874252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish application (Duraphat)
Number of subjects: 21
Study 30874252 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular brushing)
Number of subjects: 21
Study 30130715 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and marijuana co-use (AM)
Number of subjects: 277
Study 30130715 — intervention group
Group type: COMPARATOR
Intervention: Alcohol only (AO)
Number of subjects: 277
Study 26769303 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐8389 (oral doses once daily for 14 days)
Number of subjects: 0
Study 26769303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral doses once daily for 14 days)
Number of subjects: 0
Study 24961184 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 84
Study 24961184 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 84
Study 21947316 — intervention group
Group type: EXPERIMENTAL
Intervention: D: ‐amphetamine 10 mg
Number of subjects: 36
Study 21947316 — intervention group
Group type: EXPERIMENTAL
Intervention: D: ‐amphetamine 20 mg
Number of subjects: 36
Study 21947316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19081638 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ultra-brief pulse ECT at 1.5 times seizure threshold
Number of subjects: 81
Study 19081638 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ultra-brief pulse ECT at 6 times seizure threshold
Number of subjects: 81
Study 17803464 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprex
Number of subjects: 93
Study 17803464 — intervention group
Group type: COMPARATOR
Intervention: GerEPO
Number of subjects: 93
Study 17803464 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Eprex and GerEPO
Number of subjects: 93
Study 15222054 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d for 7 days)
Number of subjects: 20
Study 15222054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 g/d for 7 days)
Number of subjects: 20
Study 15046691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD)
Number of subjects: 68
Study 15046691 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD)
Number of subjects: 68
Study 9845254 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8566997 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory displays (musical graphs)
Number of subjects: 0
Study 8566997 — intervention group
Group type: COMPARATOR
Intervention: Visual line graphs
Number of subjects: 0
Study 1978470 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride 75-300 mg twice daily
Number of subjects: 89
Study 1978470 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5-20 mg twice daily
Number of subjects: 89
Study 605682 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping at once
Number of subjects: 906
Study 605682 — intervention group
Group type: COMPARATOR
Intervention: Distribution of smoking cessation program over several days
Number of subjects: 906
Study 605682 — intervention group
Group type: COMPARATOR
Intervention: Extract of avena sativa
Number of subjects: 906
Study 30472023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2,403 mg/d
Number of subjects: 1247
Study 30472023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study 27886407 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX002 (0.3, 1, 3, 10, or 30 mg/kg)
Number of subjects: 40
Study 27886407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25471255 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular moderate exercise during pregnancy
Number of subjects: 336
Study 25471255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 336
Study 23325325 — intervention group
Group type: EXPERIMENTAL
Intervention: Davunetide (5 and 30 mg/day)
Number of subjects: 63
Study 23325325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21876641 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75% cream applied daily until complete clearance or a maximum of 8 weeks
Number of subjects: 534
Study 21876641 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5% cream applied daily until complete clearance or a maximum of 8 weeks
Number of subjects: 534
Study 21876641 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied daily until complete clearance or a maximum of 8 weeks
Number of subjects: 534
Study 19570991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic plus resistance exercise (HAC)
Number of subjects: 3042
Study 18181332 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI (NVP)
Number of subjects: 69
Study 18181332 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI (EFV)
Number of subjects: 69
Study 18181332 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI (NVP and EFV combined)
Number of subjects: 69
Study 18181332 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4% decrease at week 12
Number of subjects: 69
Study 14981868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification including changes in diet and activity; no specific dosage or duration mentioned.
Number of subjects: 0
Study 14981868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy or surgery; details not specified.
Number of subjects: 0
Study 11685304 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-NIMV (inspiratory pressure=14.3+/‐1.8 cmH2O; expiratory pressure=none)
Number of subjects: 18
Study 11685304 — intervention group
Group type: EXPERIMENTAL
Intervention: IPPB
Number of subjects: 18
Study 11685304 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-Spacer
Number of subjects: 18
Study 11685304 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-NIMV
Number of subjects: 18
Study 9713266 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenorrhoea after adjuvant chemotherapy
Number of subjects: 1196
Study 9713266 — intervention group
Group type: EXPERIMENTAL
Intervention: Three initial CMF courses
Number of subjects: 1196
Study 9713266 — intervention group
Group type: EXPERIMENTAL
Intervention: ER/PR positive tumours
Number of subjects: 1196
Study 9713266 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary amenorrhoea
Number of subjects: 1196
Study 7978210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine cardioplegia (100 mg/l)
Number of subjects: 141
Study 7978210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine cardioplegia
Number of subjects: 141
Study 7978210 — intervention group
Group type: COMPARATOR
Intervention: Control group (cardioplegia without lignocaine)
Number of subjects: 141
Study 2730828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine infusion
Number of subjects: 80
Study 2730828 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 779298 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone (test name A 41 304 from Hoechst Aktiengesellschaft)
Number of subjects: 46
Study 779298 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate preparation (control)
Number of subjects: 46
Study 30454850 — intervention group
Group type: EXPERIMENTAL
Intervention: SMEDS formulation (500 mg EPA + DHA)
Number of subjects: 23
Study 30454850 — intervention group
Group type: COMPARATOR
Intervention: Standard ω-3 acid EE formulation (840 mg EPA + DHA)
Number of subjects: 23
Study 30454850 — intervention group
Group type: EXPERIMENTAL
Intervention: SMEDS formulation
Number of subjects: 23
Study 25924567 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 31
Study 26242295 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of vitamin D (100,000 IU on day 1, then 2 and 4 weeks after surgery) followed by maintenance dose (3420 IU/day)
Number of subjects: 50
Study 26242295 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by standard dose of vitamin D (3420 IU/day)
Number of subjects: 50
Study 26242295 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study 23855173 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Abrasion + 36% Phosphoric acid-etch + Conseal F
Number of subjects: 144
Study 23855173 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser + Acid Etch + Prime & Bond NT + Conseal F
Number of subjects: 144
Study 23855173 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control) + various bonding agents
Number of subjects: 144
Study 23855173 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser pretreatment + Acid Etch + Prime & Bond + Conseal F
Number of subjects: 144
Study 23855173 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Abrasion pretreatment + Acid Etch + Prime & Bond + Conseal F
Number of subjects: 144
Study 20883428 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC (pantoprazole 40 mg b.i.d., amoxicillin 1.0 g b.i.d., clarithromycin 500 mg b.i.d. for 7 days)
Number of subjects: 170
Study 20883428 — intervention group
Group type: COMPARATOR
Intervention: PBMT (pantoprazole 40 mg b.i.d., colloidal bismuth subcitrate 220 mg b.i.d, metronidazole 400 mg t.i.d., tetracycline 750 mg b.i.d. for 10 days)
Number of subjects: 170
Study 20883428 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 170
Study 20883428 — intervention group
Group type: COMPARATOR
Intervention: PBMT
Number of subjects: 170
Study 20883428 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori strains
Number of subjects: 170
Study 18675400 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Modification Program (IMP)
Number of subjects: 27
Study 18675400 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study 15940132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 79
Study 12969999 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled flunisolide (ICS), 1 mg, four inhalations bid for 7 days
Number of subjects: 58
Study 12969999 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (OCS), 2 mg/kg (max 60 mg/d) for 7 days
Number of subjects: 58
Study 10372436 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 42
Study 10372436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 42
Study 10372436 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 42
Study 8768186 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterimages of 2-8 dots
Number of subjects: 3
Study 8768186 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterimages of 2-4 linearly configured dots
Number of subjects: 3
Study 8768186 — intervention group
Group type: COMPARATOR
Intervention: Nonafterimage control conditions
Number of subjects: 3
Study 8768186 — intervention group
Group type: EXPERIMENTAL
Intervention: Briefly presented stimuli disabling eye movements
Number of subjects: 3
Study 1881720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Ig) therapy
Number of subjects: 235
Study 1881720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 7055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline, 500 mg, four times daily for 7 days
Number of subjects: 113
Study 7055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg, four times daily for 7 days
Number of subjects: 113
Study 7055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, 250 mg, four times daily for 7 days
Number of subjects: 113
Study 7055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline, 500 mg, four times daily for 10 days
Number of subjects: 113
Study 7055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole, 500 mg, four times daily for 10 days
Number of subjects: 113
Study 7055176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, loading dose plus additional ampicillin for 3 to 21 days
Number of subjects: 113
Study 31725176 — intervention group
Group type: EXPERIMENTAL
Intervention: RAFT (Rapid Appraisal for Trafficking) screening tool
Number of subjects: 0
Study 31725176 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data assessment by trained data collectors
Number of subjects: 0
Study 29700801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-based anesthesia
Number of subjects: 24
Study 29700801 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anesthesia
Number of subjects: 24
Study 27733519 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 day cefditoren pivoxil regimen
Number of subjects: 104
Study 27733519 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day cefditoren pivoxil regimen
Number of subjects: 104
Study 24922557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone Beam CT (CBCT)
Number of subjects: 0
Study 24922557 — intervention group
Group type: COMPARATOR
Intervention: Panoramic imaging
Number of subjects: 0
Study 23689765 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone, 20 mg/d (n = 108)
Number of subjects: 212
Study 23689765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 104)
Number of subjects: 212
Study 19880676 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690,550 5 mg bid
Number of subjects: 264
Study 19880676 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690,550 15 mg bid
Number of subjects: 264
Study 19880676 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690,550 30 mg bid
Number of subjects: 264
Study 19880676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 18591750 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (specific dosage and duration not mentioned)
Number of subjects: 0
Study 16616745 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti-müllerian hormone (AMH) levels in patients with premature ovarian failure (POF)
Number of subjects: 0
Study 16616745 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti-müllerian hormone (AMH) levels in patients with polycystic ovary syndrome (PCOS)
Number of subjects: 0
Study 16616745 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AMH evaluation
Number of subjects: 0
Study 14655922 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor vigilance test (PVT)
Number of subjects: 15
Study 14655922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking
Number of subjects: 15